The Combined Seed Extracts of Cassia Obtusifolia Linne and Foeniculum Vulgare Mill in Patients With Chronic Constipation

Chronic Constipation Clinical Trial

Official title:

Evaluation of Efficacy and Safety of the Combined Seed Extracts of Cassia Obtusifolia Linne and Foeniculum Vulgare Mill in Patients With Chronic Constipation: a Double-blind, Randomized, Placebo-controlled Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05548842
• Other study ID #: 02-2022-010
• Status: Completed
• Phase: N/A
• Start date: July 1, 2022
• Est. completion date: December 31, 2023

Study information

• Verified date: April 2024
• Source: Pusan National University Yangsan Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators will conduct a randomized, double-blind, placebo-controlled study to investigate the effects and safety of the combination seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill in patients with chronic constipation for 4 weeks.

Description:

A previous animal study has indicated that the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill have a laxative effect by recovering stool parameters, colonic morphology, and activation of mAchRs and their downstream signaling pathway in constipation. Furthermore, this study provides that the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill could be considered as a therapeutic drug candidate for the prevention or treatment of constipation. Therefore, the investigators a randomized, double-blind, placebo-controlled study to investigate the effects and safety of the combination seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill in patients with chronic constipation for 4 weeks. The Investigators examine stool transit time, constipation Visual Analogue Scale (VAS), Bristol stool Form scale type 3 and 4 (frequency per week), VAS for Irritable Bowel Syndrome (VAS-IBS) questionnaire, IBS severity scoring system, BS Quality of Life instrument at baseline, as well as after 2 and 4 weeks of intervention. Interferon-1β and tumor necrosis factor-α concentrations were measured at baseline and 4 weeks. One hundred adults were administered either 1,000 mg of the combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill or a placebo each day for 4 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 100
• Est. completion date: December 31, 2023
• Est. primary completion date: December 30, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 19 Years to 75 Years

Eligibility

Inclusion Criteria:

*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis

**Must include two or more of the following:

• Straining during more than ¼ (25%) of defecations

• Lumpy or hard stools (Bristol Stool Form Scale 1-2) more than ¼ (25%) of defecations

• Sensation of incomplete evacuation more than ¼ (25%) of defecations

• Sensation of anorectal obstruction/blockage more than ¼ (25%) of defecations

• Manual maneuvers to facilitate more than ¼ (25%) of defecations (e.g., digital evacuation, support of the pelvic floor)

• Fewer than three spontaneous bowel movements per week

• Loose stools are rarely present without the use of laxatives

• Insufficient criteria for irritable bowel syndrome

Exclusion Criteria:

• A person who is taking a constipation treatment prescribed by a doctor within 1 month from the date of screening

• Those who have been taking lactobacillus or probiotics within the last 1 month

• Those with secondary constipation induced by drugs or diseases.

• Abnormal liver or renal function (more than twice the normal upper limit of the research institute)

• Uncontrolled diabetes mellitus (>160 mg/dL of fasting blood sugar)

• Uncontrolled hypertension (>160/100 mmHg)

• Uncontrolled thyroid diseases.

• Those who are taking drugs, functional foods, herbs, etc. that may affect depression

• Alcohol abuser

• Allergic reaction to this test food

• Those who participated in other drug clinical trials within 1 month from the screening date.

• Severe gastrointestinal symptoms such as heartburn and indigestion

• Those who are pregnant, lactating, or plan to become pregnant during the clinical trial

• Those who are judged to be unsuitable by the PI for other reasons

Related Conditions & MeSH terms

• Chronic Constipation
• Constipation

Intervention

Dietary Supplement:
• The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill
The combined seed extracts of Cassia obtusifolia Linne and Foeniculum vulgare Mill 1,000 mg/day for 4 weeks
• Placebo group
Placebo 1,000 mg/day for 4 weeks

Locations

Country	Name	City	State
Korea, Republic of	Pusan National University Yangsan Hospital	Yangsan	Gyeungsangnam-do

Sponsors (1)

Lead Sponsor	Collaborator
Pusan National University Yangsan Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Colonic transit time during 2 weeks	The number of retained radiopaque markers on a Day 4 plain abdominal film	At the 2nd weeks after the start of the study
Primary	Change in Colonic transit time during 4 weeks	The number of retained radiopaque markers on a Day 4 plain abdominal film	At the 4th weeks after the start of the study
Secondary	Change in Constipation Visual Analogue Scale during 2 weeks	The minimum score was 0, the maximum score was 100, and higher scores mean a worse outcome.	At the 2nd weeks after the start of the study
Secondary	Change in Bristol stool Form scale type 3 and 4 (frequency per week) during 2 weeks	Frequency of Bristol stool Form scale types 3 and 4 per week	At the 2nd weeks after the start of the study
Secondary	Change in Visual Analogue Scale for Irritable Bowel Syndrome during 2 weeks	All except item 1 are rated from 0 to 100 points using the Visual Analogue Scale. A total of 700 points is obtained. Higher scores mean a better outcome.	At the 2nd weeks after the start of the study
Secondary	Change in Irritable Bowel Syndrome severity scoring system during 2 weeks	Among the questions, categorical questions asking about abdominal pain or bloating are excluded from the score calculation, and the remaining 5 questions are rated from 0 to 100 points using the Visual Analogue Scale. The total score is 500 points. Higher scores mean a worse outcome.	At the 2nd weeks after the start of the study
Secondary	Change in Irritable Bowel Syndrome Quality of Life instrument during 2 weeks	5 points for 'not at all', 4 points for 'somewhat', 3 points for 'moderate', 2 points for 'very much', and 1 point for 'severe' (i.e., count opposite the number on the questionnaire). Higher scores indicate higher quality of life.	At the 2nd weeks after the start of the study
Secondary	Change in Interferon-1ß during 4 weeks	concentration (U/ml)	At 4th weeks after the start of the study
Secondary	Change in Tumor necrosis factor-a during 4 weeks	concentration (pg/ml)	At 4th weeks after the start of the study
Secondary	Change in Constipation Visual Analogue Scale during 4 weeks	The minimum score was 0, the maximum score was 100, and higher scores	At the 4th weeks after the start of the study
Secondary	Change in Bristol stool Form scale type 3 and 4 (frequency per week) during 4 weeks	Frequency of Bristol stool Form scale types 3 and 4 per week	At the 4th weeks after the start of the study
Secondary	Change in Visual Analogue Scale for Irritable Bowel Syndrome during 4 weeks	All except item 1 are rated from 0 to 100 points using the Visual Analogue Scale. A total of 700 points is obtained. Higher scores mean a better outcome.	At the 4th weeks after the start of the study
Secondary	Change in Irritable Bowel Syndrome severity scoring system during 4 weeks	Among the questions, categorical questions asking about abdominal pain or bloating are excluded from the score calculation, and the remaining 5 questions are rated from 0 to 100 points using the Visual Analogue Scale. The total score is 500 points. Higher scores mean a worse outcome.	At the 4th weeks after the start of the study
Secondary	Change in Irritable Bowel Syndrome Quality of Life instrument during 4 weeks	5 points for 'not at all', 4 points for 'somewhat', 3 points for 'moderate', 2 points for 'very much', and 1 point for 'severe' (i.e., count opposite the number on the questionnaire). Higher scores indicate higher quality of life.	At the 4th weeks after the start of the study